In 2016, Professor Sharma led a seminal publication on Drug-Radiotherapy combinations in Nature Reviews Clinical Oncology. The open-access paper is available here
We have just received breaking news that, following peer review, the Combined Analysis paper of the FOXFIRE, SIRFLOX and FOXFIRE-Global clinical studies led by Professor Sharma has been accepted for fast-track publication in The Lancet Oncology. The full scientific article will be published this year.
Professor Sharma will present the largest prospective randomised study ever performed in Interventional Oncology at the Annual Meeting of the American Society of Clinical Oncology in Chicago. The FOXFIRE Combined Analysis was a study of 1,103 patients randomised to receive either standard first-line chemotherapy for colorectal cancer that has spread to the liver, or the same chemotherapy plus a treatment procedure called selective internal radiotherapy using radioactive yttrium-90 resin microspheres. Colorectal cancer is the fourth most frequently diagnosed cancer worldwide, and the third leading cause of cancer deaths, taking almost 700,000 lives annually. More than half of all patients with colorectal cancer will be diagnosed with metastases, most commonly in the liver.
Dr Tom Richards has been invited to be guest speaker at the UK Radiation Oncology Congress in Manchester on 14th June 2017. He will summarise the current radiotherapy treatment strategies for rectal cancer and discuss future developments and ongoing trials in this area.
Precision Oncology UK was set up in early 2017 by three consultant clinical oncologists to provide the best possible levels of care and treatment to patients with cancer using the very latest techniques in radiotherapy technology.
Dr Sibtain, Professor Sharma and Dr Richards are experts in evidence-based cancer treatments with state-of-the-art treatments. Dr Sibtain commented: "Our blend of experience, expertise and a cohesive team approach mean the best quality standards are always met, across a wide range of treatment methods."
The three consultants work together to deliver the whole package of care each patient requires.
Dr Richards added: "By working as a team, we can ensure no gaps in care and the highest levels of continuity for all patients under our joint care."
Over the past 3 years, Professor Ricky Sharma has been leading an international Joint Working Group uniquely made up of academia (NCRI CTRad), the pharma and medical device industries and patient representatives. The group provides guidance on how to combine new drugs with radiotherapy. In 2016, the Joint Working Group published their first landmark paper of consensus statements. In response to this paper, an important step forward has been made by the U.S. Food and Drug Administration, which has designed its first ever workshop on this important clinical topic. Professor Sharma spoke on this topic in Bethesda, USA, on 3rd May. For more details of the Accelerating Anticancer Agent Development and Validation Workshop or NCRI CTRad: visit this link
The goal is to make effective drug-radiotherapy combinations reach patients more quickly.